HF4852 — Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

HF4852 — Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council. · Informed CitizenryHF 4852 amends Minnesota Statutes regarding the Formulary Committee, which oversees the state's preferred drug list and prior authorization requirements. The bill allows Formulary Committee members…Open in Informed Citizenry